A Randomized, Double-blind, Parallel Group, 26-week Study Evaluating the Efficacy, Safety and Tolerability of NVA237 Given Once or Twice Daily, in Patients With Moderate and Severe Chronic Obstructive Pulmonary Disease

Trial Profile

A Randomized, Double-blind, Parallel Group, 26-week Study Evaluating the Efficacy, Safety and Tolerability of NVA237 Given Once or Twice Daily, in Patients With Moderate and Severe Chronic Obstructive Pulmonary Disease

Completed
Phase of Trial: Phase IV

Latest Information Update: 03 May 2017

At a glance

  • Drugs Glycopyrrolate (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 29 Mar 2017 Status changed from recruiting to completed.
    • 07 Mar 2017 This trial has been completed in Poland (end date: 2016-11-16), according to European Clinical Database record.
    • 28 Jan 2017 This trial was completed in Hungary, according to European Clinical Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top